Prolintane
 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Catovit, Katovit, Promotil, Villescon |
| Routes of administration | By mouth, intranasal, rectal |
| Drug class | Stimulant; Norepinephrine–dopamine reuptake inhibitor (NDRI) |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.007.077 |
| Chemical and physical data | |
| Formula | C15H23N |
| Molar mass | 217.356 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 133 °C (271 °F) |
| Boiling point | 153 °C (307 °F) |
| |
| |
  (what is this?) (verify) | |
Prolintane is a central nervous system (CNS) stimulant[2] and norepinephrine–dopamine reuptake inhibitor (NDRI) developed in the 1950s.[3] Being an amphetamine derivative, it is closely related in chemical structure to other drugs such as pyrovalerone, MDPV, and propylhexedrine, and has a similar mechanism of action.[4] Many cases of prolintane abuse have been reported.[5]
Under the brand name Katovit, prolintane was commercialized by the Spanish pharmaceutical company FHER until 2001. It was most often used by students and workers as a stimulant to provide energy and increase alertness and concentration.[medical citation needed]
See also
- α-PVP (β-ketone-prolintane, prolintanone)
- Methylenedioxypyrovalerone (MDPV)
- Pyrovalerone (Centroton, Thymergix)
- Phenylpropylaminopentane (PPAP)
References
- ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
- ^ Hollister LE, Gillespie HK (March–April 1970). "A new stimulant, prolintane hydrochloride, compared with dextroamphetamine in fatigued volunteers". The Journal of Clinical Pharmacology and the Journal of New Drugs. 10 (2): 103–9. doi:10.1177/009127007001000205. PMID 4392006.
- ^ GB Patent 807835
- ^ Nicholson AN, Stone BM, Jones MM (November 1980). "Wakefullness and reduced rapid eye movement sleep: studies with prolintane and pemoline". British Journal of Clinical Pharmacology. 10 (5): 465–72. doi:10.1111/j.1365-2125.1980.tb01790.x. PMC 1430138. PMID 7437258.
- ^ Kyle PB, Daley WP (September 2007). "Domestic abuse of the European rave drug prolintane". Journal of Analytical Toxicology. 31 (7): 415–8. doi:10.1093/jat/31.7.415. PMID 17725890.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |